Close

Mylan Pharma rolls out generic benign prostatic hyperplasia drug

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Buying Guide: How to Source High-Quality Selank for Research

Peptide research continues to expand across academic and independent...

CSPC Pharmaceutical and AstraZeneca form Biologics Joint Venture

CSPC Pharmaceutical and AstraZeneca have signed a joint venture...

Bristol Myers Squibb Expands Strategic AI Partnership with Schrรถdinger

Bristol Myers Squibb has expanded its ongoing strategic partnership...
- Advertisement -

Mylan Pharmaceuticals has introduced Alfuzosin Hydrochloride Extended-release Tablets, 10mg.Mylan’s Alfuzosin Hydrochloride Extended-release Tablets, 10mg are generic equivalent to Uroxatral, indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. Uroxatral belongs to a group of drugs called alpha-adrenergic blockers.Uroxatral relaxes the muscles in the prostate and bladder neck, making it easier to urinate.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast โ€“ stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Latest stories

Related stories

Buying Guide: How to Source High-Quality Selank for Research

Peptide research continues to expand across academic and independent...

CSPC Pharmaceutical and AstraZeneca form Biologics Joint Venture

CSPC Pharmaceutical and AstraZeneca have signed a joint venture...

Bristol Myers Squibb Expands Strategic AI Partnership with Schrรถdinger

Bristol Myers Squibb has expanded its ongoing strategic partnership...

O-1A Visa Evidence for Pharma and Biotech Professionals: What Actually Proves Extraordinary Ability

Important pharmaceutical work is not always publicly visible. A medicinal...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป